Veratric Acid

Veratric Acid

SCHEMBL3662041

[2H]C([2H])([2H])Oc1ccc(C(=O)O)cc1OC([2H])([2H])[2H]

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.75
CA1 P00915 1/20 0.75
CA2 P00918 1/20 0.75
CA4 P22748 1/20 0.75
CA6 P23280 1/20 0.75
CA7 P43166 1/20 0.75
TPMT P51580 1/20 0.75
CA9 Q16790 1/20 0.75
CA14 Q9ULX7 1/20 0.75
TSHR P16473 4/20 0.59
TTR P02766 2/20 0.56
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
RAB9A P51151 3/20 0.55
ALDH1A1 P00352 3/20 0.55
GAA P10253 3/20 0.55
KDM4E B2RXH2 3/20 0.55
HTT P42858 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Veratric Acid SCHEMBL976032 0.86 CA12 (1.00) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL114848 0.86 CA12 (1.00) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL29386353 0.86 CA12 (1.00) CA12CA1CA2CA4CA6
Vanillic Acid SCHEMBL31557599 0.85 HTT (0.77) CA12CA1CA2CA4CA6
Vanillic Acid SCHEMBL31557598 0.85 HTT (0.77) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL28597713 0.84 CA12 (0.96) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL3779944 0.84 CA12 (0.96) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL5804511 0.84 CA12 (0.96) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL9513127 0.84 CA12 (0.96) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL28276206 0.84 CA12 (0.96) CA12CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084464-B2 Tetrahydroisoquinoline derivatives CONCERT PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-8084464-B2 Tetrahydroisoquinoline derivatives CONCERT PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
EP-2231155-A1 TETRAHYDROISOQUINOLINE DERIVATIVES Concert Pharmaceuticals Inc. (US) 2010-09-29 EP disclosed
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2009-07-30 US disclosed
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2009-07-30 US disclosed
WO-2009079637-A1 TETRAHYDROISOQUINOLINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2009-06-25 WO disclosed
US-20080039473-A1 PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS AUSPEX PHARMACEUTICALS, INC. (US) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192188-A1 TETRAHYDROISOQUINOLINE DERIVATIVES HCRTR2, HCRTR1, OXTR CA12 2710/4885CA1 1117/4885CA2 674/4885
US-20080039473-A1 PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS ADRB1, ADRB2, ADRB3 CA12 4588/4885CA1 4714/4885CA2 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.